Assess whether biosimilarity is analytically justified (172976)

Situation

Clinical-development physician in a biologics company planning a biosimilar pathway has one working extract — biosimilar analytical similarity report — after a payer demanding RWE the protocol cannot generate. If biosimilar analytical similarity report cannot support biosimilarity is analytically justified, the honest Pharma & Life Sciences output is hold.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• Biosimilar analytical similarity report reads as Proceed under protocol once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to Pause the pathway after a payer demanding RWE the protocol cannot generate; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in biosimilar analytical similarity report for clinical-development physician in a biologics company planning a biosimilar pathway.
• Biosimilar analytical similarity report is missing the fact clinical-development physician needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether biosimilar analytical similarity report supports the labeled claim clinical-development physician would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a payer demanding RWE the protocol cannot generate and write the one fact that would move biosimilarity is analytically justified for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.